An immunoassay that distinguishes real neuromyelitis optica signals from a labeling detected in patients receiving natalizumab

Table 4 Serological data for 167 subjects included in the study

Natallizumab treatment	Number of patients	Group	False labeling pattern
Yes	20	2	17*
No	147	1-6	0

*These patients were on natalizumab at the time blood samples were taken or stopped receiving this drug less than 6 months prior to collection of the blood sample.

ISSN: 1471-2377